Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Amit Sanyal, MD: A Clinician’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Apr
29
Today In Oncology
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Neoadjuvant Durvalumab and Chemotherapy in Triple-Negative Breast Cancer: Long-Term Follow-Up of GeparNuevo Trial
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Do Political Beliefs Shape Views on Clinical Trials in Cancer?
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo